Inmedical Therapeutics closed a first funding round of €800,000 with participation from Viscofan and Basque FCR (managed by Gestión de Capital Riesgo del País Vasco - Grupo Spri). The operation was led and advised by Elkargi, which handled analysis, valuation, structure, investor search, and negotiation of terms. Founded in 2020 and formed by four companies including I+Med, the Vitoria-Gasteiz–based startup is developing a medical device product referred to in the article as Covergel/Convergel to reduce complications in therapeutic endoscopies. Convergel is described as an easy-to-use, cost-effective bioadhesive regenerative platform that covers resection sites to prevent delayed bleeding and perforation while accelerating mucosal healing; the technology is transformable toward other medical solutions. The company has completed preclinical studies and has initiated clinical trials at several hospitals in the Basque Country, with a plan to begin commercialization in 2025 if results are positive.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024